- Home
- IOVA
as 06-20-2025 4:00pm EST
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 771.4M | IPO Year: | N/A |
| Target Price: | $12.22 | AVG Volume (30 days): | 11.2M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.64 - $12.51 | Next Earning Date: | 08-07-2025 |
| Revenue: | $212,679,000 | Revenue Growth: | 11070.12% |
| Revenue Growth (this year): | 86.62% | Revenue Growth (next year): | 69.95% |
Stock Insider Trading Activity of Iovance Biotherapeutics Inc. (IOVA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kirby Daniel Gordon | IOVA | Chief Commercial Officer | Jun 5 '25 | Buy | $1.84 | 30,000 | $55,200.00 | 30,000 | |
| Puri Raj K. | IOVA | Chief Regulatory Officer | May 23 '25 | Buy | $1.74 | 5,600 | $9,743.44 | 206,852 | |
| Vogt Frederick G | IOVA | Interim CEO & General Counsel | May 14 '25 | Buy | $1.69 | 25,000 | $42,250.00 | 374,646 |
Latest Iovance Biotherapeutics Inc. News
IOVA Breaking Stock News: Dive into IOVA Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Iovance Biotherapeutics CFO Jean-Marc Bellemin to Depart
GlobeNewswire
11 days ago
Iovance Biotherapeutics to Present at Upcoming Conference
GlobeNewswire
19 days ago
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
Insider Monkey
a month ago
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma
GlobeNewswire
a month ago
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
Motley Fool
a month ago
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Motley Fool
a month ago
Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
Motley Fool
a month ago
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today
Compare IOVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOVA Iovance Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.